Physician profile
Jose Serrano
NPI 1386669778
$8,142.67
in general payments reported to CMS, 2019-2025
35 companies · $860 in 2025
The $860 reported for 2025 was more than what 90% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,464 · 2020: $1,208 · 2021: $1,139 · 2022: $850 · 2023: $1,439 · 2024: $1,184 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,384 · Education: $98.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,384.20 |
| Education | $98.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,144.33 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $982.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $919.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $677.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $614.42 | 2019-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $503.58 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $470.69 | 2019-2024 | Xarelto |
| Pfizer INC. | $419.05 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $344.31 | 2019-2022 | |
| Abbvie INC. | $255.22 | 2019-2024 | Ubrelvy, Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.90 | 2019-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $223.85 | 2019-2021 | |
| Astellas Pharma US INC | $222.60 | 2023-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $128.40 | 2019-2021 | |
| Exact Sciences Corporation | $120.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $118.43 | 2024-2025 | Voquezna |
| Abbott Laboratories | $114.05 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Allergan, INC. | $103.38 | 2019-2020 | |
| Radius Health, INC. | $70.16 | 2024-2025 | Tymlos |
| Otsuka America Pharmaceutical, INC. | $68.81 | 2019-2025 | Rexulti |
| Amgen INC. | $64.69 | 2019-2024 | Otezla, Repatha, Evenity |
| Sumitomo Pharma America, INC. | $52.24 | 2023-2024 | Gemtesa |
| Eisai INC. | $48.45 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.60 | 2022 | |
| Arbor Pharmaceuticals, INC. | $26.18 | 2019-2020 | |
| Corcept Therapeutics | $24.17 | 2025 | Korlym |
| Biogen, INC. | $23.38 | 2024 | Spinraza |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.68 | 2022 | |
| Nevro Corp. | $18.43 | 2023 | Senza |
| Xeris Pharmaceuticals, INC. | $16.67 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.99 | 2024 | Givlaari |
| Idorsia Pharmaceuticals US INC | $15.87 | 2022 | |
| Corium, LLC | $14.63 | 2022 | |
| Cvrx, INC. | $13.02 | 2025 | Barostim Neo System |
| Phadia US INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Serrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.